Halozyme Therapeutics, Inc. (HALO)
71.71
+1.28
(+1.82%)
USD |
NASDAQ |
Jan 21, 16:00
71.71
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Accounts Receivable (Quarterly): 346.04M for Sept. 30, 2025
Accounts Receivable (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Accounts Receivable (Quarterly) Benchmarks
| Johnson & Johnson | -- |
| Merck & Co., Inc. | 12.12B |
| AIM ImmunoTech, Inc. | -- |
| Stryker Corp. | 3.643B |
| Skye Bioscience, Inc. | -- |